Ampio Pharmaceuticals, Inc. (AMPE)

OTC • Currency in USD

$0.08

$0.00

0.00%

Last Update: 2 Sept 2025, 18:00

$94.80K

Market Cap

0.00

P/E Ratio (TTM)

—

Forward Dividend Yield

$0.00 - $0.13

52 Week Range

AMPE Stock Price Chart

Explore Ampio Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze AMPE price movements and trends.

AMPE Company Profile

Discover essential business fundamentals and corporate details for Ampio Pharmaceuticals, Inc. (AMPE) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

31 Mar 2010

Employees

6.00

Website

https://www.ampiopharma.com

CEO

Michael A. Martino

Description

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

AMPE Financial Timeline

Browse a chronological timeline of Ampio Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Earnings released on 28 Apr 2025

Earnings released on 28 Mar 2025

Earnings released on 13 Nov 2024

Earnings released on 30 Sept 2024

Earnings released on 24 May 2024

Earnings released on 27 Mar 2024

EPS came in at -$2.48 , while revenue for the quarter reached $245.00K .

Earnings released on 14 Nov 2023

EPS came in at -$1.53 surpassing the estimated -$6.00 by +74.50%.

Stock split effective on 12 Sept 2023

Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 8 Aug 2023

EPS came in at -$1.80 surpassing the estimated -$6.00 by +70.00%.

Earnings released on 8 May 2023

EPS came in at -$5.20 surpassing the estimated -$6.00 by +13.33%.

Earnings released on 27 Mar 2023

EPS came in at -$3.60 surpassing the estimated -$6.00 by +40.00%.

Earnings released on 14 Nov 2022

EPS came in at -$10.00 falling short of the estimated -$0.02 by -49.90K%.

Stock split effective on 10 Nov 2022

Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 9 Aug 2022